Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes

Translational Oncology

Volumn 2, Issue 4, 2009, Pages 341-349

  Pejovic, Tanja ^a   Pande, Nupur T ^a   Mori, Motomi ^a   Mhawech Fauceglia, Paulette ^b   Harrington, Christina ^a   Mongoue Tchokote, Solange ^a   Dim, Daniel ^b   Andrews, Christopher ^b   Beck, Amy ^b   Tarumi, Yukie ^a   Djilas, Jovana ^a   Cappuccini, Fabio ^a   Caballero, Otavia ^c   Huang, Jiaqi ^d   Levy, Samuel ^d   Tsiamouri, Alexia ^d   Cain, Joanna ^a   Bagby, Grover C ^e   Strausberg, Robert L ^d   Simpson, Andrew J ^c   Odunsi, Kunle O ^b   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d J CRAIG VENTER INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALK; CELL SURFACE PROTEIN; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR B1; EPIDERMAL GROWTH FACTOR RECEPTOR 4; INSRR; MEMBRANE PROTEIN; PTK; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA SEQUENCE; EARLY DIAGNOSIS; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MALIGNANT TRANSFORMATION; OVARY CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

EID: 77953375710     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09199     Document Type: Article

References (25)

1. ChenWJ, ChenHW, Yu SL,HuangCH,WangTD, Chen JJ,ChienCT, ChenHY, Yang PC, and Lee YT (2005). Gene expression profiles in hypoxic preconditioning using cDNA microarray analysis: altered expression of an angiogenic factor, carcinoembryonic antigen-related cell adhesion molecule 1. Shock 24, 124-131.
2. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al. (2004). Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10, 3291-3300.
3. Scholl S, Beuzeboc P, and Pouillart P (2001). Targeting HER2 in other tumor types. Ann Oncol 12 (Suppl 1), S81-S87.
4. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57, 289-300.
5. Cary, NC (1999). SAS/STAT User's Guide, Version 8. Cary, NC: STAT Publishing Inc.
6. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29.
7. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847.
8. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busgam D, Li K, Edwards JB, Eberhard C, et al. (2005). Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 102, 14344-14349.
9. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, et al. (2006). Dominantnegative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 103, 5799-5804.
10. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, et al. (2008). EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7, 1098-1103.
11. Kiyokawa E, Takai S, Tanaka M, Iwase T, Suzuki M, Xiang YY,Naito Y, Yamada K, Sugimura H, and Kino I (1994). Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 54, 3645-3650.
12. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, Lincoln D, Boyle G, Parson PG, and Boyd AW (2006). Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6, 144.
13. Gilmour LM, Macleod KG, McCaig A, Gullick WJ, Smyth JF, and Langdon SP (2001). Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res 61, 2169-2176.
14. Srinivasan R, Gillett CE, Barnes DM, and Gullick WJ (2000). Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 60, 1483-1487.
15. Witton CJ, Going JJ, Cooke TG, and Bartlett JM (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200, 290-297.
16. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, et al. (2001). HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell 21, 4265-4275.
17. Vidal GA, Anjali Naresh A,Marrero L, and Jones FE (2005). Presenilin-dependent γ-secretase processing regulates multiple ERBB4/HER4 activities. JBC 280, 19777-19783.
18. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, Moon SW, Park WS, Nam SW, Lee JY, Yoo NJ, et al. (2006). Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 118, 1426-1429.
19. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
20. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, and Cho KR (2006). Fibroblast growth factor 9 has oncogenic activity and is a downstreamtarget of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66, 1354-1362.
21. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357.
22. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et al. (2002). Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62, 4722-4729.
23. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, and Hampton GM (2001). Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98, 1176-1181.
24. Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, and Berchuck A (2004). Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11, 51-59.
25. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, and Longacre TA (2005). Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96, 684-694.